Alpine Immune Sciences, Inc. - Common Stock (NQ:ALPN)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, May 17, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Alpine Immune Sciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

General Mills, Lennar And 3 Stocks To Watch Heading Into Wednesday ↗

September 21, 2022

With US stock futures trading slightly lower this morning on Wednesday, some of the stocks that may grab investor focus today are as follows:

Via Benzinga

Alpine Immune Sciences Announces Pricing of $100 Million Public Offering

September 20, 2022

From Alpine Immune Sciences, Inc.

Via Business Wire

Alpine Immune Sciences Announces Proposed Public Offering

September 20, 2022

From Alpine Immune Sciences, Inc.

Via Business Wire

At R&D Day, Alpine Immune Highlights Updates On Autoimmune, Immuno-Oncology Programs ↗

September 13, 2022

Via Benzinga

Alpine Immune's Davoceticept Monotherapy Reduces Tumors In Early Stage Study ↗

April 13, 2022

Alpine Immune Sciences Inc (NASDAQ: ALPN)

Via Benzinga

Alpine Immune Sciences to Highlight Clinical Updates on Autoimmune and Immuno-Oncology Programs at Inaugural R&D Day

September 12, 2022

From Alpine Immune Sciences, Inc.

Via Business Wire

Alpine Immune Sciences Announces Participation in September Investor Conferences

September 06, 2022

From Alpine Immune Sciences Inc.

Via Business Wire

Alpine Immune Sciences's Return On Capital Employed Overview ↗

September 06, 2022

Benzinga Pro data, Alpine Immune Sciences (NASDAQ:ALPN) reported Q2 sales of $5.29 million. Earnings fell to a loss of $18.10 million, resulting in a 140.44% decrease from last quarter.

Via Benzinga

Alpine Immune Sciences Announces R&D Day to Provide Clinical Updates on Wholly-Owned Programs ALPN-303 and Davoceticept

August 30, 2022

From Alpine Immune Sciences, Inc.

Via Business Wire

Alpine Immune Sciences Announces Inducement Grant to Andrew S. Sandler, M.D. Under Nasdaq Listing Rule 5635(c)

August 18, 2022

From Alpine Immune Sciences, Inc.

Via Business Wire

Alpine Immune Sciences: Q2 Earnings Insights ↗

August 11, 2022

Alpine Immune Sciences (NASDAQ:ALPN) reported its Q2 earnings results on Thursday, August 11, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Via Benzinga

Alpine Immune Sciences Provides Corporate Update and Reports Second Quarter 2022 Financial Results

August 11, 2022

From Alpine Immune Sciences, Inc.

Via Business Wire

Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial ↗

August 10, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Evotec, Alpine Expand Pact For Commercial Process Development Of Autoimmune Disease Candidate ↗

August 10, 2022

Via Benzinga

Just – Evotec Biologics and Alpine Immune Sciences Expand Partnership for Commercial Process Development of ALPN-303

August 10, 2022

From Alpine Immune Sciences Inc.

Via Business Wire

Alpine Immune Sciences Announces Participation in Fireside Chat at the 2022 Wedbush PacGrow Healthcare Virtual Conference

August 04, 2022

From Alpine Immune Sciences, Inc.

Via Business Wire

Alpine Immune Sciences Appoints Jörn Drappa, MD, PhD, to Board of Directors

July 19, 2022

From Alpine Immune Sciences Inc.

Via Business Wire

Alpine Immune Sciences Appoints Andrew S. Sandler, M.D. as Chief Medical Officer

June 07, 2022

From Alpine Immune Sciences, Inc.

Via Business Wire

Alpine Immune Sciences Announces Update on ALPN-303, a Dual BAFF/APRIL Inhibitor for Systemic Lupus Erythematosus and Other Autoimmune and Inflammatory Diseases, at EULAR 2022

June 01, 2022

From Alpine Immune Sciences Inc.

Via Business Wire

The Week Ahead In Biotech (May 30-June 4): FDA Decision For Eton's Partnered Epilepsy Drug, ASCO Conference Gets Underway And More ↗

May 30, 2022

Biotech stocks advanced in the week ended May 27, tracking the overall positive sentiment of the broader market. Notwithstanding the week's strength, the sector has been one of the worst performers for...

Via Benzinga

Alpine Immune Sciences Announces Presentations at the 2022 EULAR and ASCO Annual Meetings

May 26, 2022

From Alpine Immune Sciences, Inc.

Via Business Wire

FDA Lifts Partial Hold On Alpine Immune's Davoceticept Combo Trial In Advanced Cancer ↗

May 24, 2022

Via Benzinga

Alpine Immune Sciences Announces FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab

May 24, 2022

From Alpine Immune Sciences, Inc.

Via Business Wire

Alpine Immune Sciences Provides Corporate Update and Reports First Quarter 2022 Financial Results

May 12, 2022

From Alpine Immune Sciences, Inc.

Via Business Wire

Alpine Immune Sciences Announces Participation in May Investor Conferences

May 03, 2022

From Alpine Immune Sciences, Inc.

Via Business Wire

AACR 2022: Davoceticept (ALPN-202) Monotherapy Reduces Tumors, Supports Multiple Expansion Cohorts

April 12, 2022

From Alpine Immune Sciences Inc.

Via Business Wire

The Daily Biotech Pulse: Aeglea Stock Jumps On Inherited Metabolic Disease Data, Partial Hold Lifted On Gilead's 2 Blood Trials, Early Data From Novartis' KRAS Inhibitor And More ↗

April 12, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More ↗

April 10, 2022

Biotech stocks managed to carve out modest gains for the week ending April 8, defying the broader market weakness. The defensive nature of the stocks make them appealing in times of risk aversion.

Via Benzinga

Alpine Immune Sciences Announces Company Presentation and Update on AACR Investor Event

April 05, 2022

From Alpine Immune Sciences Inc.

Via Business Wire

Alpine Immune Sciences Publishes Key Preclinical Rationale for Davoceticept (ALPN-202), a First-in-Class CD28 Costimulator and Dual Checkpoint Inhibitor, in Nature Communications

April 04, 2022

From Alpine Immune Sciences, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.